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Superﬁcial Femoral Artery
Real-World Versus Randomized Clinical Trials;
You Choose, But Caveat Emptor!*Andrew J. Klein, MDR andomized clinical trials (RCT) are consid-ered the pinnacle of the research pyramid,but they often include patients and/or lesion
subsets that are not found as commonly in the “real
world.” In this issue of JACC: Cardiovascular Inter-
ventions, Yokoi et al. (1) report the “real-world” re-
sults from a post-market surveillance study of the
Zilver drug-eluting stent ([DES]; Cook Medical, Bloo-
mington, Indiana) for the treatment of obstructive
atherosclerotic disease of the superﬁcial femoral
artery (SFA). This Japanese study of 907 patientsSEE PAGE 271provides a glimpse of how these stents respond in
nontrial patients who often have more diffuse disease
and more comorbidities than most trial patients do.
However, we must recognize that stenting the SFA is
very different from stenting the left anterior descend-
ing coronary artery and that the DES data in the SFA
vascular bed is very small in comparison to the coro-
nary bed; although these results at ﬁrst glance are
impressive, they must be seen in the context of the
general literature—may the buyer beware!
The movement in the periphery from percutaneous
transluminal angioplasty (PTA) to bare-metal stents
(BMS) to potential drug-eluting technologies mirrors
what was seen over the past 3 decades in the coronary
realm. Similarly, stenting has been shown to be
superior to PTA alone in the femoropopliteal arterial*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From the Department of Vascular and Endovascular Medicine, John
Cochran VA Medical Center, St. Louis University School of Medicine, St.
Louis, Missouri. Dr. Klein has reported that he has no relationships
relevant to the contents of this paper to disclose.bed (2,3), except when lesions are short (<50 mm) (4).
These trials, published in high-proﬁle journals, led
many to assume a stent-ﬁrst strategy given the ease
of deployment and the small residual stenosis often
seen with stenting. Interventionalists, used to the
0% residual stenosis seen with coronary stents, often
desire similar results in the peripheral vessels.
However, the restenosis rates of BMS in the femo-
ropopliteal artery far exceed those seen in the coro-
nary realm. These high rates are likely secondary to
the diffuse, calciﬁc, and often occlusive nature of
the disease found in this arterial bed, as well as the
well-documented complex biophysical forces exerted
on these vessels with daily movement (5). These
forces manifest themselves in stent fracture, which
has been associated with in-stent restenosis and is
more common with older stent designs (6). Contem-
porary stent designs show lower rates of stent frac-
ture, but neointimal hyperplasia leading to restenosis
and reocclusion has remained the Achilles heel of
endovascular therapy of this vascular bed, under-
scoring that one treatment does not ﬁt all when it
comes to arterial beds. As in the coronary vasculature,
there has been a movement toward drug-eluting
technologies to preclude neointimal hyperplasia.
Initial studies with DES, however, have yielded less
than optimal results. In the SIRROCO (Sirolimus-
Coated Cordis Self-Expandable Stent) trial (7), the drug
sirolimus was mounted on a S.M.A.R.T. stent (Cordis
Corp., Fremont, California) and failed to show any
difference in restenosis at 12 months when compared
with the non–drug-coated S.M.A.R.T. stent. Similarly,
the STRIDES (Superﬁcial Femoral Artery Treatment
with Drug-Eluting Stents) study (8), a single-arm study
of an everolimus stent with no comparative group in
short lesions (mean lesion length was 9 cm)
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rate of 32%.
Despite these initial disappointing results, the
pursuit of an effective DES for the femoropopliteal
segment continued. The Zilver PTX trial (9), pub-
lished in 2011, was an RCT of a mere 236 patients
randomized to either PTA or a Zilver DES for treat-
ment of the SFA. In the 120 patients (50%) who failed
PTA alone, a second randomization was performed
between a Zilver BMS and a Zilver DES. Compared
with PTA alone, the DES group showed a dramatic
primary patency rate of 74.8% versus 26.5% at
24 months. Although these absolute percentages are
impressive, astute readers have underscored that the
high crossover rate of this RCT essentially means that
25% of the control group had the intervention tested,
which dilutes the beneﬁt as well as any risks of the
DES (10). The lesions included in this RCT also were
short with an average length of 65 mm and are
generally considered easy to treat; most would be
categorized as TASC (TransAtlantic Inter-Society
Consensus) A/B (11) and as such, it is not surprising
that these lesions did well with endovascular therapy.
In this study by Yokoi et al. (1), we see how the
Zilver DES responds in a real-world Japanese cohort
study of 907 patients (58.8% diabetic, 43.8% chronic
kidney disease, and 21.5% with critical limb
ischemia), wherein Zilver DES were used to treat
various conditions (41.6% occlusions, 18.6% reste-
nosis of BMS). In this cohort, a total of 1,861 stents
were placed to treat 1,075 lesions, demonstrating a
freedom from target lesion revascularization rate of
91.0% and a primary patency rate of 86.4% at 1 year.
Although these numbers are impressive, delving
deeper into who these patients are reveals that many
of them had only Rutherford class I or II claudication,
which naturally will dampen the number of patients
needing clinically driven target vessel revasculariza-
tion, because these patients approximately one-third
of the cohort had mild symptoms at baseline. Thus,
the astute reader will cautiously interpret the “post-
treatment clinical beneﬁt” outcome measure and
focus more on those patients who had an ultrasound.
Duplex surveillance was performed in 65% of patients
and demonstrated an ultrasound-based patency of86% at 12 months. Such an endpoint, although com-
mon in femoral trials, has been questioned because
its validity for predicting symptoms of impending
occlusion is not certain (10). The investigators also
relate that their study stands in contrast to another
“real-world” clinical study from Japan called the
ZEPHYR (Zilver PTX for the Femoral Artery and
Proximal Popliteal Artery) study (12). Zephyr included
slightly more diabetics and critical limb ischemia
patients, but it demonstrated a 1-year patency rate
of 68% using the Zilver DES, a major adverse limb
event rate of 22%, and a stent thrombosis rate of 2%
in 690 patents with 831 femoropopliteal lesions.
So which study is correct? Is the 1-year patency 86%
or 68%? Caveat emptor indeed!
The other major issue that plagues operators, in-
surance companies, and patients is the cost of these
devices that must be weighed against the cost of
repeat procedures. To date, there are no U.S. cost-
effectiveness studies nor any comparative effective-
ness studies of DES versus drug-eluting balloon.
Although the rate of stent fracture is very low, the
long-term impact of a permanent metal scaffold is
unknown, and whether there will be a late catch-up
phase of these technologies or the development of
new atheroma within these stents is also uncertain.
No matter what treatment is chosen, both we and
the patient enter into a long-term contract of sur-
veillance by clinical assessment, functional testing,
and imaging when any intervention to the femo-
ropopliteal bed is performed, which mirrors what is
demanded of our colleagues in vascular surgery when
they perform lower-extremity bypass grafting (10).
We must be constantly vigilant and weary of all data
from peripheral vascular trials, as the numbers of
both the RCT and “real-world” studies are small in
comparison to the coronary realm, and enthusiasm
for new devices must be tempered with the realism
that the SFA is not the left anterior descending
coronary artery: caveat emptor!
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